| 产品描述: | 组织蛋白酶B抑制剂。胱天蛋白酶抑制剂的阴性对照。;Cathepsin B inhibitor. Negative control for caspase inhibitors.;; |
| 体内研究: |
Z-FA-FMK (1 mg/kg;瘤内注射;每 2 天一次,持续 27 天; HT1080 荷瘤 SCID 小鼠) 在体内阻断呼肠孤病毒感染。 Z- FA-FMK (8 mg/kg;iv;每 2 d,一次;雄性 BALB/c 小鼠) 显著减轻 D-GalN/TNF-α 诱导的肾损伤的损伤程度。 |
| 参考文献: |
1. Lopez-Hernandez FJ, et, al. Z-FA-fmk inhibits effector caspases but not initiator caspases 8 and 10, and demonstrates that novel anticancer retinoid-related molecules induce apoptosis via the intrinsic pathway. Mol Cancer Ther. 2003 Mar;2(3):255-63. 2. Kim M, et, al. Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis in vivo. Antivir Ther. 2010;15(6):897-905. 3. Gezginci-Oktayoglu S, et, al. Effects of Z-FA.FMK on D-galactosamine/tumor necrosis factor-alpha-induced kidney injury and oxidative stress in mice : effects of Z-FA.FMK on TNF-alpha-mediated kidney injury. Mol Cell Biochem. 2008 Feb;309(1-2):9-20. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.588 ml |
12.939 ml |
25.879 ml |
| 5 mM |
0.518 ml |
2.588 ml |
5.176 ml |
| 10 mM |
0.259 ml |
1.294 ml |
2.588 ml |
| 50 mM |
0.052 ml |
0.259 ml |
0.518 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |